Startups
WHO WE ARE
BIOLIFE4D is a pioneering biotech company leveraging current advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation – lifesaving technology that ultimately gives patients the gift of time.
And you can get involved.
WHAT WE DO
Operated by seasoned business leaders, guided by world-class biomedical and life science experts, and financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death worldwide.
BIOLIFE4D’s groundbreaking process represents a convergence of recent breakthroughs in regenerative medicine, adult stem cell biology, computer technology, and cutting-edge manufacturing techniques – all of which will make organ replacement commercially viable and commonplace globally.
WHY?
We are committed to perfecting the technology to make viable organ replacement a safe, accessible and affordable reality.
The movement begins soon. Join us today.
BIOLIFE4D is a pioneering biotech company leveraging current advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation – lifesaving technology that ultimately gives patients the gift of time.
And you can get involved.
WHAT WE DO
Operated by seasoned business leaders, guided by world-class biomedical and life science experts, and financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death worldwide.
BIOLIFE4D’s groundbreaking process represents a convergence of recent breakthroughs in regenerative medicine, adult stem cell biology, computer technology, and cutting-edge manufacturing techniques – all of which will make organ replacement commercially viable and commonplace globally.
WHY?
We are committed to perfecting the technology to make viable organ replacement a safe, accessible and affordable reality.
The movement begins soon. Join us today.
Overview
Location
United States, Illinois, Buffalo Grove
Employees
1-10
Phone
224-602-9569
Founded date
2015
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 14, 2022 | Nuclera raises another $15.5M towards launch of gene protein 3D bioprinting technology | Biotechnology start-up Nuclera has attracted a further $15.5 million in Series B funding, taking its total raised in the round up to $58 million. Much like the initial $42.5 million it raised earlier this year, Nuclera plans to use this add... |
| Jun 23, 2022 | IperionX announces listing on the Nasdaq stock exchange | Sustainable, low-cost titanium developer IperionX (IPX) has become listed on the Nasdaq stock exchange. IperionX began trading on Nasdaq under the ticker ‘IPX’ on June 21, 2022, while also maintaining its listing on the Australian Securitie... |
| Jun 9, 2022 | BIOLIFE4D seeking to finance heart 3D bioprinting plans via $17.5M IPO in the US | Biotechnology specialist BIOLIFE4D has filed for an Initial Public Offering (IPO) with the US Securities and Exchange Commission (SEC). Though BIOLIFE4D has yet to price its IPO, it has revealed that it aims to raise $17.5 million via the m... |
| Jul 23, 2020 | Today at MedCity INVEST: Healthcare investment strategies amidst a pandemic and biopharma startups compete | This week we are hosting our annual MedCity INVEST conference online. Today’s agenda includes a panel discussion on investment trends and the biopharma track of the Pitch Perfect contest. The conference kicked off July 20 and concludes on F... |
| Jun 24, 2020 | Meet biopharma finalists for MedCity virtual INVEST event: Register now for Earlybird tickets while they last | Our annual INVEST conference will be held as a virtual event this year. We will highlight the seismic changes in healthcare from July 20-24 and spotlight top startups and growth stage companies and how healthcare innovation is contending wi... |
| Jun 30, 2018 | Scientists successfully printed 3D human heart tissue | Scientists at Chicago based biotech startup BIOLIFE4D this week announced a major breakthrough that is the ability to 3D print human cardiac tissue. The scientific milestone was accomplished shortly after the opening of the company’s new r... |
| Today at MedCity INVEST: Healthcare investment strategies amidst a pandemic and biopharma startups compete | This week we are hosting our annual MedCity INVEST conference online. Today’s agenda includes a panel discussion on investment trends and the biopharma track of the Pitch Perfect contest. The conference kicked off July 20 and concludes on F... | |
| Meet biopharma finalists for MedCity virtual INVEST event: Register now for Earlybird tickets while they last | Our annual INVEST conference will be held as a virtual event this year. We will highlight the seismic changes in healthcare from July 20-24 and spotlight top startups and growth stage companies and how healthcare innovation is contending wi... |
Reviews 0
FAQ about BIOLIFE4D
When was BIOLIFE4D founded?
BIOLIFE4D was founded in 2015.
What has the press written about BIOLIFE4D?
Parsers VC has collected 9 articles mentioning BIOLIFE4D, among them “Nuclera raises another $15.5M towards launch of gene protein 3D bioprinting technology” (Jul 14, 2022) and “IperionX announces listing on the Nasdaq stock exchange” (Jun 23, 2022).
Is BIOLIFE4D still active?
Yes, BIOLIFE4D is active; its latest activity on Parsers VC dates from Sep 9, 2022.